Dewpoint Therapeutics has entered a collaboration with Chemify to expedite the discovery of molecules that target cancer and neurodegeneration.
The companies will leverage the programmable chemistry platform of Chemify to develop an array of digitally discovered and automatically synthesised new molecules against specific condensate targets in the oncology and neurodegeneration pipeline of Dewpoint.
The collaboration will combine Chemify’s chemistry artificial intelligence (AI) and automation technology platform with the condensate biology and AI technology platform of Dewpoint.
Chemify’s platform can design, discover and generate complex molecules leveraging a chemical programming language.
Furthermore, the company’s newly developed automated design, discovery and synthesis platform will be used to expedite the efforts of Dewpoint.
Under the deal, Chemify will carry out the design and delivery of new compounds to boost Dewpoint’s pipeline.
Dewpoint also holds an option to purchase the Chemify-designed compounds for which the former will make clinical and regulatory milestones, as well as tiered royalty payments.
Dewpoint Therapeutics CEO Ameet Nathwani said: “Dewpoint’s partnership with Chemify offers an innovative pathway to take our novel chemical matter already in optimisation and bootstrap Chemify’s novel chemical space exploration tool suite using state-of-the-art digital chemistry AI-powered concepts.
“This is a new frontier for drug discovery and we are delighted to partner with Chemify, who is at the cutting edge of this approach.”
Dewpoint applies its knowledge in biomolecular condensates to drug discovery for various ailments or ones that result from condensate dysfunction.
The company has programmes across a pipeline spread over oncology, neurodegenerative, cardiopulmonary and metabolic diseases fields.